As we at Budding Trends reported last week, the DEA is set to finally accept the recommendation of the U.S. Department of Health and Human Services (HHS) to reschedule marijuana from Schedule I to Schedule III under the...more
5/7/2024
/ Administrative Law Judge (ALJ) ,
Cannabis Products ,
Congressional Review Act ,
Controlled Substances Act ,
DEA ,
Decriminalization of Marijuana ,
Department of Health and Human Services (HHS) ,
Final Rules ,
Judicial Review ,
Legislative Agendas ,
Marijuana ,
Marijuana Related Businesses ,
Medical Marijuana ,
Notice of Proposed Rulemaking (NOPR) ,
OMB ,
Public Comment ,
Regulatory Agenda ,
Schedule I Drugs ,
State and Local Government
For as long as there have been rules of evidence and courtrooms, there have been products that can impair litigants or witnesses—and products whose use carries the potential to trigger certain stigmas in the eyes of the...more
11/13/2023
/ Admissible Evidence ,
Agribusiness ,
Cannabis Products ,
Controlled Substances Act ,
Crime-Fraud Exception ,
Farm Bill ,
Federal v State Law Application ,
Legalization ,
Litigation Privilege ,
Litigation Strategies ,
Marijuana ,
Rules of Evidence
In a recent article, we noted that beverage industry giants have announced future plans to explore the CBD beverage market — a market that has an expected valuation of $1.4 billion by 2023....more
As states around the country continue to liberalize cannabis rules, an increasing number of industries are transitioning into the market — and the next on the horizon may be the hospitality industry.
Not surprisingly,...more
For several years, industry giants such as Coca-Cola, PepsiCo, and Anheuser-Busch have made waves announcing future plans to explore the CBD-beverage market. And last week, Nasdaq published an article on the future of...more
2/8/2022
/ Agribusiness ,
Beverage Manufacturers ,
Cannabidiol (CBD) oil ,
Cannabis Products ,
Federal Trade Commission (FTC) ,
Food & Drug Regulations ,
Food and Drug Administration (FDA) ,
Hospitality Industry ,
Labeling ,
Nasdaq ,
Regulatory Agenda
While we enter a new season this week, the same cannot be said for the FDA which, on November 16, reiterated that its approach to regulating the cannabidiol (CBD) industry will be “the same as it ever was”—a regulatory...more
12/1/2021
/ Cannabidiol (CBD) oil ,
Cannabis Products ,
Cannabis-Related Businesses (CRBs) ,
Dietary Supplements ,
False Advertising ,
Food and Drug Administration (FDA) ,
Health and Safety ,
Labeling ,
Legislative Agendas ,
Medical Foods ,
Regulatory Oversight
Texas’s cannabis industry can breathe a momentary sigh of relief. Delta-8 THC, the increasingly popular hemp-derived cannabinoid that produces effects similar to Delta-9 THC, has been removed from Texas’s list of Schedule I...more
11/12/2021
/ Administrative Procedure Act ,
Cannabis Products ,
Cannabis-Related Businesses (CRBs) ,
Centers for Disease Control and Prevention (CDC) ,
Controlled Substances ,
Farm Bill ,
Food and Drug Administration (FDA) ,
Hemp ,
Marijuana Related Businesses ,
State and Local Government ,
Texas ,
THC
On July 14, 2021, Senate Majority Leader Chuck Schumer (D-NY), Senate Finance Committee Chairman Ron Wyden (D-OR), and Sen. Cory Booker (D-NJ) unveiled a draft of the Cannabis Administration and Opportunity Act.
The...more